TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05469126
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06441318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered at protocol defined dose.
Study: NCT06278948
Drug: Group CYS
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application short contact, of thin layer once daily at bedtime for 4 months
Study: NCT05668897
Drug: placebo of GST-HG171
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Study: NCT06307223
Drug: supramolecular active zinc
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
Study: NCT05923918
Drug: PBK_M2101 2-Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
Study: NCT05923918
Drug: PBK_M2101 1-Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
Study: NCT05450913
Drug: Priformis intramuscular injection with %2 lidocain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
Study: NCT04912843
Drug: NR082 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection（IVT）
Study: NCT00990301
Drug: Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.
Approvals — FDA: no, EMA: no, PMDA: no
Description: test drug
Study: NCT00990301
Drug: Uniretic® 15mg/25mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: reference drug
Study: NCT04449965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be performed twice daily for two weeks.
Study: NCT06122389
Drug: SHR2554; Chidamide analog tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 + Chidamide analog tablets
Study: NCT06122389
Drug: SHR2554 analog tablets; Chidamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 analog tablets + Chidamide
Study: NCT05728736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken nightly for two consecutive nights
Study: NCT00662077
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate endovenous 3 mg every 3 months
Study: NCT05671627
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
Study: NCT05052853
Drug: Placebo Cap
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo as a comparator
Study: NCT04777760
Drug: two and more doses of surfactant replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
Study: NCT06123702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 placebo capsules
Study: NCT05304845
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-competitive acid blocker
Study: NCT05446961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally capsules
Study: NCT05908396
Drug: IGM-2644
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
Study: NCT05893862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05947669
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
Study: NCT04627779
Drug: preemptive analgesia with flurbiprofen axetil
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: give flurbiprofen axetil 15 min before surgery
Study: NCT05843422
Drug: 0.1% QY211 Gel or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QY211 Gel or placebo topical applied to skin
Study: NCT05843422
Drug: 0.3% QY211 Gel or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QY211 Gel or placebo topical applied to skin
Study: NCT05843422
Drug: 0.8% QY211 Gel or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QY211 Gel or placebo topical applied to skin
Study: NCT05843422
Drug: 1.5% QY211 Gel or placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QY211 Gel or placebo topical applied to skin
Study: NCT05562167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
Study: NCT06420388
Drug: Standard Postoperative Analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (Paracetamol)~Dosage: 500 mg per tablet Frequency: Every 6 hours Route: Oral~Acetaminophen is a common over-the-counter pain reliever and fever reducer. It works by blocking the production of prostaglandins, which are responsible for causing pain and inflammation.~Celecoxib~Dosage: 200 mg per tablet Frequency: Every 12 hours Route: Oral~Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits the cyclooxygenase-2 enzyme. By reducing the production of prostaglandins, celecoxib helps alleviate pain and inflammation.~Dynastat (Parecoxib)~Dosage: 40 mg per injection Frequency: Every 12 hours as needed for poorly controlled pain Route: Intravenous
Study: NCT05061420
Drug: SAR444245 (Thor-707)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion
Study: NCT06729047
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive placebo (normal saline)
Study: NCT06729047
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive ketorolac (0.5 mg/kg)
Study: NCT06729034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily
Study: NCT04745104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered through IV infusion
Study: NCT05746208
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05767060
Drug: BAT7104 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.
Study: NCT01446120
Drug: Insulin loaded Orally Dissolved Films (insulin-ODF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05719896
Drug: DT01 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject was given orally 3 DT01 tablets/day for 8 weeks
Study: NCT05719896
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject was given orally 3 DT01 tablets/day for 8 weeks
Study: NCT05719896
Drug: DT01-Placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject was given orally 2 DT01 tablets and 1 Placebo tablet, three times per day for 8 weeks
Study: NCT06455735
Drug: 68Ga-FAPI/18F-FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Study: NCT06253078
Drug: Ciprofol dose 0.4mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of ciprofol was 0.4mg/Kg for induction in this group.
Study: NCT06253078
Drug: Ciprofol dose 0.3mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of ciprofol was 0.3mg/Kg for induction in this group.
Study: NCT06253078
Drug: Ciprofol dose 0.2mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of ciprofol was 0.2mg/Kg for induction in this group.
Study: NCT06030804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Study: NCT05042908
Drug: LBL-003 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBL-003 was given every two weeks for treatment
Study: NCT05776043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 3 months
Study: NCT05009953
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
Study: NCT05009953
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
Study: NCT05588531
Drug: Group 1:YK-1169
Approvals — FDA: no, EMA: no, PMDA: no
Description: YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
Study: NCT05588531
Drug: Group 2:YK-1169/Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
Study: NCT05588531
Drug: Group 3:YK-1169/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Study: NCT05588531
Drug: Group 4:YK-1169/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Study: NCT05588531
Drug: Group 5:YK-1169/Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
Study: NCT06151808
Drug: XTR006
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
Study: NCT00002192
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002192
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03523156
Drug: Azithromycin mass treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
Study: NCT03523156
Drug: Azithromycin targeted treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two rounds of treatment targeted to all children aged 2 to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
Study: NCT06434194
Drug: PTA (Standard of Care)
Normalized name: Achillea ptarmica whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.
Study: NCT05970289
Drug: BRII-835
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRII-835 will be given via subcutaneous injection
Study: NCT05861830
Drug: Chemotherapy selected by the physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy regimen is chosen by the clinical physician and may include, but is not limited to, the following options: the combination of paclitaxel and capecitabine, the combination of paclitaxel and carboplatin, single-agent capecitabine, single-agent platinum drugs, and the combination of gemcitabine and platinum-based chemotherapy. Each treatment cycle consists of a 21-day duration.
Study: NCT04859569
Drug: LY01011
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Study: NCT04859569
Drug: Xgeva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously (SC) once every 4 weeks (Q4W)
Study: NCT06213415
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids plus intratympanic injection
Study: NCT05103241
Drug: [14C] GP681
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg suspension containing 100μCi of \[14C\]GP681
Study: NCT05758896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
Study: NCT05084859
Drug: SM08502
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM08502 to be administered orally.
Study: NCT05084859
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI Protocol to be administered intravenously.
Study: NCT05985785
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of treatment for OA of the knee is corticosteroid injection.
Study: NCT05816226
Drug: Hydrocortisone 2.5%
Normalized name: HYDROCORTISONE 2.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied four times daily to TMJ with arthralgia
Study: NCT05816226
Drug: Diclofenac 1% topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied four times daily to TMJ with arthralgia
Study: NCT04702698
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
Study: NCT04702698
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
Study: NCT04550338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of blinded medications
Study: NCT06392516
Drug: Ketoacid
Normalized name: Alpha-ketoacid carboxylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml ketoacid two hours before the hemodialysis session ended
Study: NCT05041010
Drug: Neu2000KWL group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
Study: NCT05041010
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
Study: NCT06301789
Drug: Effect of adding Mg sulfate as an adjuvant to bupivacain in U/S guided QLB for postoperative analgesia in lower abdominal cancer surgeries
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided transmuscular (anterior) quadratus lumborum block will be performed Each patient will be placed in the lateral position. the transducer will be placed in a transverse orientation on the flank just cranial to the iliac crest, then slide posteriorly to obtain an image of the quadratus lumborum muscle.echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle; the correct position of the needle tip will be confirmed by injecting 3 mL of saline to separate the fascial layers at the lateral aspect of the quadratus lumborum muscle. Thereafter, the needle will be advanced more posteriorly between the quadratus muscle and psoas major muscle
Study: NCT05271721
Drug: epidural transforaminal injection of magnesuim sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: transforaminal fluroscopic guided
Study: NCT05709301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05218070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml Saline (0.9%)
Study: NCT05626309
Drug: Qizhu Yuling Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
Study: NCT05626309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
Study: NCT06500793
Drug: PF614 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF614 capsules (25-100 mg)
Study: NCT05215665
Drug: GEMOX Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
Study: NCT04854824
Drug: Recommended treatment schedule
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Study: NCT04854824
Drug: Control treatment schedule
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens different from the recommended one according to family physician personal practice
Study: NCT05540470
Drug: PART
Normalized name: Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chloroquine(150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug~1. Primaquine (PQ) (15 mg tablets): weight-adjusted dosage. (Rationale: this short-course posology has been chosen to facilitate the adherence to treatment for asymptomatic individuals participating to the Module A, Primaquine will be administered to all participants to Module A during the induction phase of the intervention.~2. OR tafenoquine (TQ) (150 mg tablets): 2 tablets as a single dose (orally), (Rationale: the posology chosen corresponds to that used in phase III trials for the radical cure of P. vivax and the therapeutic recommendation in Brazil). Tafenoquine will only be administered during the full implementation phase to participants who do not meet exclusion criteria.
Study: NCT05540470
Drug: Malakit
Approvals — FDA: no, EMA: no, PMDA: no
Description: delivery of a sturdy, lightweight, waterproof plastic involucre that contains:~* 1 laminated sheet with illustrated instruction~* 1 complete anti-malarial treatment targeting P. falciparum, but also effective in acute forms of P. vivax with association with artemisinin derivatives~  * A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication~ * Two 15 mg tablets of primaquine, to be given as a single dose (145)~* 1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets~* 3 Malaria rapid diagnostic tests (RDTs) in individual packs and with easy-to-use retractable lancets. Three tests will be included, taking into account the possibility of having one or two negative or invalid tests before returning to a distribution site for further supplies.
Study: NCT05210439
Drug: Short-treatment of any active antibiotic regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of any active antibiotic treatment for BSI-PA
Study: NCT05210439
Drug: Long-treatment of any active antibiotic regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of any active antibiotic treatment for BSI-PA
Study: NCT05798715
Drug: Gleptomet 50/1000(Metformin HCl & Sitagliptin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT05798715
Drug: Janumet 50/1000(Metformin HCl & Sitagliptin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT00000363
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06085521
Drug: LNK01001 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken orally
Study: NCT06085521
Drug: LNK01001 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken orally
Study: NCT06085521
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken orally